UT Southwestern Medical Center, Department of Urology , 5323 Harry Hines Blvd. J8130, Dallas, TX 75390 , USA.
Expert Opin Emerg Drugs. 2013 Dec;18(4):533-50. doi: 10.1517/14728214.2013.864635.
Androgen deprivation therapy is the mainstay treatment for patients with prostate cancer who are not candidates for definitive treatment, are diagnosed with advanced disease on initial presentation or progress after primary treatment. Patients who stop responding to androgen deprivation therapy develop castration resistant prostate cancer (CRPC). Emerging drugs undergoing clinical evaluation and drugs that have recently received FDA approval for the treatment of CRPC are reviewed.
As the natural history and signaling pathways of prostate cancer are better understood, new treatments and targeted therapies will be developed. The FDA recently approved 5 medications that increase survival in patients with CRPC. Additional medications and drug classes are being explored that may eventually lead to new treatment options. Articles were identified using a PubMed database search.
Recent FDA medication approvals and the development of emerging treatments are promising for the future of patients with prostate cancer. The addition of new medications challenges physicians to identify the optimal sequence and/or combination in which newer and older medications should be administered. Physicians treating patients with prostate cancer have a growing responsibility to keep pace with these new medications so that they may counsel and treat patients appropriately.
去势治疗是不适合根治性治疗、初始诊断为晚期疾病或初始治疗后进展的前列腺癌患者的主要治疗方法。停止对去势治疗有反应的患者会发展为去势抵抗性前列腺癌（CRPC）。本文综述了正在进行临床评估的新兴药物和最近获得 FDA 批准用于治疗 CRPC 的药物。
随着对前列腺癌的自然史和信号通路的更好理解，将开发新的治疗方法和靶向治疗。FDA 最近批准了 5 种可延长 CRPC 患者生存期的药物。正在探索其他药物和药物类别，它们最终可能会带来新的治疗选择。文章通过 PubMed 数据库搜索确定。
最近 FDA 批准的药物和新兴治疗方法的发展为前列腺癌患者的未来带来了希望。新药物的加入促使医生确定新药物和旧药物的最佳顺序和/或联合应用方案。治疗前列腺癌患者的医生有越来越大的责任来跟上这些新药物的步伐，以便能够适当地为患者提供咨询和治疗。
